Chung B-H, Lee J-Y, Kim C-I, Kim C-S, Oh C-Y, Lee S-W, Lee J-S, Yoo S-J
Department of Urology, Yongdong Severance Hospital, Yonsei University Health System, Seoul, Korea.
Int J Impot Res. 2009 Jan-Feb;21(1):68-73. doi: 10.1038/ijir.2008.62. Epub 2008 Dec 11.
The sexuality and the management of benign prostatic hyperplasia (BPH) with alfuzosin (SAMBA) trial evaluated the effect of alfuzosin on sexual function in men treated for BPH using two sexual function scales: male sexual health questionnaire (MSHQ) and international index of erectile function (IIEF-15). A total of 148 patients with BPH were treated with alfuzosin for 24 weeks. The patients were followed at baseline, 4, 12 and 24 weeks after medication with alfuzosin. MSHQ was collected at every visit, whereas Q(max), IPSS and IIEF-15 were checked at baseline and end point. At the end point, Q(max) (+4.7 ml s(-1), P<0.01) and IPSS (-5.3, P<0.01) had improved significantly. Alfuzosin also significantly improved the total MSHQ (19.2%, 79.1-94.3, P<0.01) and the MSHQ ejaculatory scores (26.0%, 22.3-28.1, P=<0.01) versus baseline. Alfuzosin for the treatment of patients with BPH is effective in improving sexual function, as well as lower urinary tract symptoms (LUTSs) and quality of life, and is well tolerated.
阿夫唑嗪治疗良性前列腺增生症（BPH）的性功能及管理（SAMBA）试验，使用男性性功能问卷（MSHQ）和国际勃起功能指数（IIEF - 15）这两种性功能量表，评估了阿夫唑嗪对接受BPH治疗男性性功能的影响。共有148例BPH患者接受阿夫唑嗪治疗24周。在服用阿夫唑嗪后的基线、4周、12周和24周对患者进行随访。每次随访时收集MSHQ，而在基线和终点时检查最大尿流率（Q(max)）、国际前列腺症状评分（IPSS）和IIEF - 15。在终点时，Q(max)（增加4.7 ml s(-1)，P<0.01）和IPSS（降低5.3，P<0.01）有显著改善。与基线相比，阿夫唑嗪还显著改善了总的MSHQ（提高19.2%，从79.1至94.3，P<0.01）和MSHQ射精评分（提高26.0%，从22.3至28.1，P=<0.01）。阿夫唑嗪治疗BPH患者可有效改善性功能、下尿路症状（LUTSs）和生活质量，且耐受性良好。
